You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新冠特效藥概念股集體走強,舒泰神、翰宇藥業20CM漲停
格隆匯1月17日丨奧密克戎繼續蔓延,A股市場新冠特效藥概念股集體走強,舒泰神、翰宇藥業漲20%漲停,飛凱材料漲超13%,廣生堂漲近13%,前沿生物漲近10%,君實生物漲近9%,尖峯集團漲超8%。舒泰神於2021年9月收到中國國家藥品監督管理局簽發的STSA-1002注射液用於治療重型COVID-19的《藥物臨牀試驗批准通知書》。近日,STSA-1002注射液在北京大學人民醫院完成I期臨牀試驗(國內)的首例受試者給藥。翰宇藥業與中國科學院微生物研究所合作開發新型冠狀病毒多肽鼻噴劑藥物,截止目前,已完成化合物優化篩選以及針對新冠病毒當前兩主要流行變異株奧密克戎變異株(Omicron)及德爾塔變異株(Delta)的假病毒中和實驗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account